Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry

Journal of Medicinal Chemistry

Volumn 54, Issue 6, 2011, Pages 1539-1554

  Ishikawa, Minoru ^a   Hashimoto, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 2,3,7,8 TETRACHLORODIBENZOFURAN; 3 METHYLCHOLANTHRENE; 7 CHLORO 2,3 DIHYDRO 2(PHENYL)PYRIDAZINO[4,5 B]QUINOLINE 1,4,10 (5H) TRIONES; AMG 157; ANILIDE; AROMATIC HYDROCARBON RECEPTOR; BENZAMIDE; BENZENESULFONIC ACID DERIVATIVE; BENZO[A]PYRENE; BETA NAPHTHOFLAVONE; CARBANILAMIDE; CARBOXYL GROUP; CARBOXYLIC ACID DERIVATIVE; CIPROFLOXACIN; CYCLIN DEPENDENT KINASE INHIBITOR; DIPYRONE; FLUORINE; GYRASE INHIBITOR; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE INHIBITOR; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST; VITRONECTIN RECEPTOR BLOCKING AGENT;

ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CHEMICAL STRUCTURE; DENSITY FUNCTIONAL THEORY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG HALF LIFE; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HYDROPHOBICITY; MELTING POINT; NONHUMAN; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS;

DATABASES, FACTUAL; DRUG DISCOVERY; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; WATER;

EID: 79952804851     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101356p     Document Type: Article

References (80)

1. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and In Vivo Bioavailability Pharm. Res. 1995, 12, 413-420
2. Stegemann, S.; Leveiller, F.; Franchi, D.; de Jong, H.; Lindén, H. When Poor Solubility Becomes an Issue: From Early Stage to Proof of Concept Eur. J. Pharm. Sci. 2007, 31, 249-261 (Pubitemid 47079001)
3. Alelyunas, Y. W.; Empfield, J. R.; McCarthy, D.; Spreen, R. C.; Bui, K.; Pelosi-Kilby, L.; Shen, C. Experimental Solubility Profiling of Marketed CNS Drugs, Exploring Solubility Limit of CNS Discovery Candidate Bioorg. Med. Chem. Lett. 2010, 20, 7312-7316
4. Bhattachar, S. N.; Deschenes, L. A.; Wesley, J. A. Solubility: It's Not Just for Physical Chemists Drug Discovery Today 2006, 11, 1012-1018 (Pubitemid 44572881)
5. In this review, we define thermodynamic solubility as the solubility obtained after a solid compound has been agitated in the solvent for more than 24 h.
6. Yalkowsky, S. H. Solubility and Solubilization in Aqueous Media; American Chemical Society: Washington, DC, 1999.
7. Palucki, M.; Higgins, J. D.; Kwong, E.; Templeton, A. C. Strategies at the Interface of Drug Discovery and Development: Early Optimization of the Solid State Phase and Preclinical Toxicology Formulation for Potential Drug Candidates J. Med. Chem. 2010, 53, 5897-5905
8. Lipinski, C. A.; Lombardo, F; Dominy, B. W.; Feeney, P. J. Experimental and Computational Approaches To Estimate Solubility and Permeability in Drug Discovery and Development Settings Adv. Drug Delivery Rev. 2001, 46, 3-26 (Pubitemid 33653411)
9. Lipinski, C. A. Drug-like Properties and the Causes of Poor Solubility and Poor Permeability J. Pharmacol. Toxicol. Methods 2000, 44, 235-249 (Pubitemid 32239479)
10. Hansch, C.; Quinlan, J. E.; Lawrence, G. L. Linear Free-Energy Relationship between Partition Coefficients and the Aqueous Solubility of Organic Liquids J. Org. Chem. 1968, 33, 347-350
11. Valvani, S. C.; Yalkowsky, S. H.; Roseman, T. J. Solubility and Partitioning IV: Aqueous Solubility and Octanol-Water Partition Coefficients of Liquid Nonelectrolytes J. Pharm. Sci. 1981, 70, 502-507 (Pubitemid 11075795)
12. Banerjee, S; Yalkowsky, S. H; Valvani, S. C. Water Solubility and Octanol/Water Partition Coefficients of Organics: Limitations of the Solubility-Partition Coefficient Correlation Environ. Sci. Technol. 1980, 10, 1227-1229 (Pubitemid 10030051)
13. Jain, N.; Yalkowsky, S. H. Estimation of the Aqueous Solubility I: Application to Organic Nonelectrolytes J. Pharm. Sci. 2001, 90, 234-252 (Pubitemid 32158051)
14. Yalkowsky, S. H.; Valvani, S. C. Solubility and Partitioning I: Solubility of Non Electrolytes in Water J. Pharm. Sci. 1980, 69, 912-922 (Pubitemid 11234579)
15. Ran, Y.; Yalkowsky, S. H. Prediction of Drug Solubility by the General Solubility Equation (GSE) J. Chem. Inf. Comput. Sci. 2001, 41, 354-357 (Pubitemid 32408650)
16. Gavezzotti, A. Are Crystal Structures Predictable- Acc. Chem. Res. 1994, 27, 309-314
17. Handbook of Chemistry and Physics, 72 nd ed.; CRC Press: Boca Raton, FL, 1991.
18. Lovering, F.; Bikker, J.; Humblet, C. Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success J. Med. Chem. 2009, 52, 6752-6756
19. Hoover, T. B. Water Solubility of PCB Isomers PCB Newsl. 1971, 3, 4-5
20. Lee, M. C.; Chian, E. S. K.; Griffin, R. A. Solubility of Polychlorinated Biphenyls and Capacitor Fluid Water Water Res. 1979, 13, 1249-1258 (Pubitemid 10167175)
21. Gavezzotti, A. Molecular Symmetry, Melting Temperatures and Melting Enthalpies of Substituted Benzenes and Naphthalenes J. Chem. Soc., Perkin Trans. 2 1995, 1399-1404
22. Dannenfelser, R.-M.; Yalkowsky, S. H. Estimation of Entropy of Melting from Molecular Structure: A Non-Group Contribution Method Ind. Eng. Chem. Res. 1996, 35, 1483-1486 (Pubitemid 126460306)
23. Lipinski, C. A. In Molecular Drug Properties: Measurement and Prediction; Mannhold, R., Ed.; Methods and Principles in Medicinal Chemistry, Vol. 37; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2008; pp 257 - 282.
24. Chu, K. A.; Yalkowsky, S. H. Predicting Aqueous Solubility: The Role of Crystallinity Curr. Drug Metab. 2009, 10, 1184-1191
25. Yalkowsky, S. H.; Wu, M. Estimation of the Ideal Solubility (Crystal-Liquid Fugacity Ratio) of Organic Compounds J. Pharm. Sci. 2010, 99, 1100-1106
26. Wang, H. L.; Katon, J.; Balan, C.; Bannon, A. W.; Bernard, C.; Doherty, E. M.; Dominguez, C.; Gavva, N.; Gore, V.; Ma, V.; Nishimura, N.; Surapaneni, S.; Tang, P.; Tamir, R.; Thiel, O.; Treanor, J. J. S.; Norman, M. H. Novel Vanilloid Receptor-1 Antagonists. 3. The Identification of a Second-Generation Clinical Candidate with Improved Physicochemical and Pharmacokinetic Properties J. Med. Chem. 2007, 50, 3528-3539 (Pubitemid 47195461)
27. Doherty, E. M.; Fotsch, C.; Bannon, A. W.; Bo, Y.; Chen, N.; Dominguez, C.; Falsey, J.; Gavva, N. R.; Katon, J.; Nixey, T.; Ognyanov, V. I.; Pettus, L.; Rzasa, R. M.; Stec, M.; Surapaneni, S.; Tamir, R.; Zhu, J.; Treanor, J. J.; Norman, M. H. Novel Vanilloid Receptor-1 Antagonists: 2. Structure-Activity Relationships of 4-Oxopyrimidines Leading to the Selection of a Clinical Candidate J. Med. Chem. 2007, 50, 3415-3527
28. Brown, A.; Brown, L.; Brown, T. B.; Calabrese, A.; Ellis, D.; Puhalo, N.; Smith, C. R.; Wallace, O.; Watson, L. Triazole Oxytocin Antagonists: Identification of Aryl Ether Replacements for a Biaryl Substituent Bioorg. Med. Chem. Lett. 2008, 18, 5242-5244
29. Kim, I. H.; Heirtzler, F. R.; Morisseau, C.; Nishi, K.; Tsai, H. J.; Hammock, B. D. Optimization of Amide-Based Inhibitors of Soluble Epoxide Hydrolase with Improved Water Solubility J. Med. Chem. 2005, 48, 3621-3629 (Pubitemid 40664110)
30. 3 Dual Antagonistic Activity Bioorg. Med. Chem. 2006, 14, 2089-2108 (Pubitemid 43254728)
31. 3 Dual Antagonists Bioorg. Med. Chem. 2006, 14, 2109-2130 (Pubitemid 43254729)
32. 3 Antagonists. WO9952872, 1999.
33. 3 Dual Activity and Improved Water Solubility Bioorg. Med. Chem. 2006, 14, 2131-2150 (Pubitemid 43254730)
34. 3 Antagonists. WO0127082, 2001.
35. Mehta, J. L.; Nichols, W. W.; Mehta, P. Neutrophils as Potential Participants in Acute Myocardial Ischemia: Relevance to Reperfusion J. Am. Coll. Cardiol. 1988, 11, 1309-1316
36. Reynolds, J. M.; Mcdonagh, P. F. Early in Reperfusion, Leukocytes Alter Perfused Coronary Capillarity and Vascular Resistance Am. J. Physiol.: Heart Circ. Physiol. 1989, 256, H982-H989
37. Engler, R. L.; Dahlgren, M. D.; Morris, D. D.; Peterson, M. A.; Schmid-Schonbein, G. W. Role of Leukocytes in Response to Acute Myocardial Ischemia and Reflow in Dogs Am. J. Physiol.: Heart Circ. Physiol. 1986, 251, H314-H323
38. 3 Integrins Circulation 1998, 98, 1085-1091 (Pubitemid 28420700)
39. Cherny, R. C.; Honan, M. A.; Perumal, P. Site-Directed Mutagenesis of Arginine-Glycine Aspartic Acid in Vitronectin Abolishes Cell Adhesion J. Biol. Chem. 1993, 268, 9725-9729 (Pubitemid 23146033)
40. 1 Integrins J. Biol. Chem. 1994, 269, 20233-20238 (Pubitemid 24260416)
41. 3 Antagonists J. Am. Chem. Soc. 1996, 118, 7461-7472 (Pubitemid 26279800)
42. 3 Integrin for a New Cancer Therapy Angew. Chem., Int. Ed. Engl. 1997, 36, 1374-1389
43. Bach, A. C., II; Espina, J. R.; Jackson, S. A.; Stouten, P. F. W.; Duke, J. L.; Mousa, S. A.; DeGrado, W. F. Type II- to Type I -Turn Swap Changes Specificity for Integrins J. Am. Chem. Soc. 1996, 118, 293-294
44. Valkó, K. Application of High-Performance Liquid Chromatography Based Measurements of Lipophilicity to Model Biological Distribution J. Chromatogr., A 2004, 1037, 299-310 (Pubitemid 38591346)
45. 3 Dual Antagonists. In Soyaku Shien Kenkyu no Tenbo; Torisawa, Y., Ed.; CMC Publishing: Tokyo, 2008; pp 3 - 13.
46. 3 Org. Process Res. Dev. 2008, 12, 596-602
47. 3 and Glycoprotein IIb/IIIa Inhibition Causes Reduction in Infarct Size in a Model of Acute Coronary Thrombosis and Primary Angioplasty Cardiovasc. Res. 2005, 66, 552-561 (Pubitemid 40725767)
48. Kaul, S. Evaluating the "No Reflow" Phenomenon with Myocardial Contrast Echocardiography Basic Res. Cardiol. 2006, 101, 391-399 (Pubitemid 44275872)
49. Fujita, Y.; Yonehara, M.; Tetsuhashi, M.; Noguchi-Yachide, T.; Hashimoto, Y.; Ishikawa, M. -Naphthoflavone Analogs as Potent and Soluble Aryl Hydrocarbon Receptor Agonists: Improvement of Solubility by Disruption of Molecular Planarity Bioorg. Med. Chem. 2010, 18, 1194-1203
50. Denison, M. S.; Pandini, A.; Nagy, S. R.; Baldwin, E. P.; Bonati, L. Ligand Binding and Activation of the Ah Receptor Chem.-Biol. Interactions 2002, 141, 3-24 (Pubitemid 35229988)
51. Mimura, J.; Fujii-Kuriyama, Y. Functional Role of AhR in the Expression of Toxic Effects by TCDD Biochim. Biophys. Acta 2003, 1619, 263-268 (Pubitemid 36160604)
52. Esser, C.; Rannug, A.; Stockinger, B. The Aryl Hydrocarbon Receptor in Immunity Trends Immunol. 2009, 30, 447-454
53. Marple, L.; Brunck, R.; Throop, L. Water Solubility of 2,3,7,8-Tetrachlorodibenzo-para-dioxin Environ. Sci. Technol. 1986, 20, 180-182
54. Sugihara, K.; Okayama, T.; Kitamura, S.; Yamashita, K.; Yasuda, M.; Miyairi, S.; Minobe, Y.; Ohta, S. Comparative Study of Aryl Hydrocarbon Receptor Ligand Activities of Six Chemicals in Vitro and In Vivo Arch. Toxicol. 2008, 82, 5-11
55. Holth, T. F.; Beylich, B. A.; Skarphedinsdottir, H.; Liewenborg, B.; Grung, M.; Hylland, K. Genotoxicity of Environmentally Relevant Concentrations of Water-Soluble Oil Components in Cod (Gadus morhua) Environ. Sci. Technol. 2009, 43, 3329-3334
56. All calculations were carried out with a Gaussian 03 program package. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, J.; Jaramillo, R.; Gomperts, R. E.; Stratmann, O.; Yazyev, A. J.; Austin, R.; Cammi, C.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, revision E.01; Gaussian, Inc.: Wallingford, CT, 2004.
57. Kasuga, J.; Ishikawa, M; Yonehara, M.; Makishima, M.; Hashimoto, Y.; Miyachi, H. Improvement of Water-Solubility of Biarylcarboxylic Acid Peroxisome Proliferator-Activated Receptor (PPAR) -Selective Partial Agonists by Disruption of Molecular Planarity/Symmetry Bioorg. Med. Chem. 2010, 18, 7164-7173
58. Kliewer, S. A.; Forman, B. M.; Blumberg, B.; Ong, E. S.; Borgmeyer, U.; Mangelsdorf, D. J.; Umesono, K.; Evans, R. M. Differential Expression and Activation of a Family of Murine Peroxisome Proliferator-Activated Receptors Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7355-7359 (Pubitemid 24226862)
59. Gross, B.; Staels, B. PPAR Agonists: Multimodal Drugs for the Treatment of Type-2 Diabete Best Pract. Res., Clin. Endocrinol. Metab. 2007, 21, 687-710 (Pubitemid 350177568)
60. Tanaka, T.; Yamamoto, J.; Iwasaki, S.; Asaba, H.; Hamura, H.; Ikeda, Y.; Watanabe, M.; Magoori, K.; Ioka, R. X.; Tachibana, K.; Watanabe, Y.; Uchiyama, Y.; Sumi, K.; Iguchi, H.; Ito, S.; Doi, T.; Hamakubo, T.; Naito, M.; Auwerx, J.; Yanagisawa, M.; Kodama, T.; Sakai, J. Activations of Peroxisome Proliferators-Activated Receptor Delta Induces Fatty Acid Beta-Oxidation in Skeletal Muscle and Attenuates Metabolic Syndrome Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 15924-15929 (Pubitemid 38021091)
61. Lee, C. H.; Olson, P.; Hevener, A.; Mehl, I.; Chong, L. W.; Olefsky, J. M.; Gonzalez, F. J.; Ham, J.; Kang, H.; Peters, J. M.; Evans, R. M. PPAR- Regulates Glucose Metabolism and Insulin Sensitivity Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 3444-3449 (Pubitemid 43346488)
62. Epple, R.; Cow, C.; Xie, Y.; Azimioara, M.; Russo, R.; Wang, X.; Wityak, J.; Karanewsky, D. S.; Tuntland, T.; Nguya-Trân, V. T.; Cuc Ngo, C.; Huang, D.; Saez, E.; Spalding, T.; Gerken, A.; Iskandar, M.; Seidel, H. M.; Tian, S. S. Novel Bisaryl Substituted Thiazoles and Oxazoles as Highly Potent and Selective Peroxisome Proliferator-Activated Receptor - Agonists J. Med. Chem. 2010, 53, 77-105
63. Sauerberg, P.; Olsen, G. S.; Jeppesen, L.; Mogensen, J. P.; Pettersson, I.; Jeppesen, C. B.; Daugaard, J. R.; Galsgaard, E. D.; Ynddal, L.; Fleckner, J.; Panajotova, V.; Polivka, Z.; Pihera, P.; Havranek, M.; Wulff, E. M. Identification and Synthesis of a Novel Selective Partial PPAR- Agonist with Full Efficacy on Lipid Metabolism in Vitro and In Vivo J. Med. Chem. 2007, 50, 1495-1503 (Pubitemid 46564371)
64. Kasuga, J.; Ishida, S.; Yamasaki, D.; Makishima, M.; Doi, T.; Hashimoto, Y.; Miyachi, H. Novel Biphenylcarboxylic Acid Peroxisome Proliferator-Activated Receptor (PPAR) - Selective Antagonists Bioorg. Med. Chem. Lett. 2009, 19, 6595-6599
65. Bergström, C. A.; Wassvik, C. M.; Johansson, K.; Hubatsch, I. Poorly Soluble Marketed Drugs Display Solvation Limited Solubility J. Med. Chem. 2007, 50, 5858-5862 (Pubitemid 350106040)
66. Anderson, D. R.; Meyers, M. J.; Vernier, W. F.; Mahoney, M. W.; Kurumbail, R. G.; Caspers, N.; Poda, G. I.; Schindler, J. F.; Reitz, D. B.; Mourey, R. J. Pyrrolopyridine Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2) J. Med. Chem. 2007, 50, 2647-2654 (Pubitemid 46896072)
67. Dublanchet, A. C.; Ducrot, P.; Andrianjara, C.; O'Gara, M.; Morales, R.; Compere, D.; Denis, A.; Blais, S.; Cluzeau, P.; Courté, K.; Hamon, J.; Moreau, F.; Prunet, M.-L.; Tertre, A. Structure-Based Design and Synthesis of Novel Non-Zinc Chelating MMP-12 Inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 3787-3790 (Pubitemid 41038979)
68. Leach, A. G.; Jones, H. D.; Cosgrove, D. A.; Kenny, P. W.; Ruston, L.; MacFaul, P.; Wood, J. M.; Colclough, N.; Law, B. Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties: A Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure J. Med. Chem. 2006, 49, 6672-6682 (Pubitemid 44749735)
69. Jones, C. D.; Andrews., D. M.; Barker, A. J. Imidazole Pyrimidine Amides as Potent, Orally Bioavailable Cyclin-Dependent Kinase Inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 6486-6489
70. Schroeder, G. M.; An, Y.; Cai, Z.-W.; Chen, X.-T.; Clark, C.; Cornelius, L. A. M.; Dai, J.; Gullo-Brown, J.; Gupta, A.; Henley, B.; Hunt, J. T.; Jeyaseelan, R.; Kamath, A.; Kim, K.; Lippy, J.; Lombardo, L. J.; Manne, V.; Oppenheimer, S.; Sack, J. S.; Schmidt, R. J.; Shen, G.; Stefanski, K.; Tokarski, J. S.; Trainor, G. L.; Wautlet, B. S.; Wei, D.; Williams, D. K.; Zhang, Y.; Zhang, Y.; Fargnoli, J.; Borzilleri, R. M. Discovery of N -(4-(2-Amino-3- chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1, 2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily J. Med. Chem. 2009, 52, 1251-1254
71. Brown, D. G.; Urbanek, R. A.; Bare, T. M.; McLaren, F. M.; Horchler, C. L.; Murphy, M.; Steelman, G. B.; Empfield, J. R.; Forst, J. M.; Herzog, K. J.; Xiao, W.; Dyroff, M. C.; Lee, C.-M. C.; Trivedi, S.; Neilson, K. L.; Keith, R. A. Synthesis of 7-Chloro-2,3-dihydro-2-[1-(pyridinyl)alkyl]-pyridazino[4,5- b ]quinoline-1,4,10(5 H)-triones as NMDA Glycine-Site Antagonists Bioorg. Med. Chem. Lett. 2003, 13, 3553-3556 (Pubitemid 37141428)
72. Fray, J. M.; Bull, D. J.; Carr, C. L.; Gautier, E. C. L.; Mowbray, C. E.; Stobie, A. Structure-Activity Relationships of 1,4-Dihydro-(1 H,4 H)-quinoxaline-2,3-diones as N -Methyl- d -aspartate (Glycine Site) Receptor Antagonists. 1. Heterocyclic Substituted 5-Alkyl Derivatives J. Med. Chem. 2001, 44, 1951-1962 (Pubitemid 32884519)
73. Ballard, P.; Bradbury, R. H.; Harris, C. S.; Hennequin, L. F.; Hickinson, M.; Kettle, J. G.; Kendrew, J.; Klinowska, T.; Ogilvie, D. J.; Pearson, S. E.; Williams, E. J.; Wilson, I. Inhibitors of Epidermal Growth Factor Receptor Tyrosine Kinase: Optimisation of Potency and In Vivo Pharmacokinetics Bioorg. Med. Chem. Lett. 2006, 16, 4908-4912 (Pubitemid 44209131)
74. Li, X.; Manjunatha, U. H.; Goodwin, M. B.; Knox, J. E.; Lipinski, C. A.; Keller, T. H.; Barry, C. E.; Dowd, C. S. Synthesis and Antitubercular Activity of 7-(R)- and 7-(S)-Methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7- dihydro-5 H -imidazo[2,1- b ][1,3]oxazines, Analogues of PA-824 Bioorg. Med. Chem. Lett. 2008, 18, 2256-2262 (Pubitemid 351442913)
75. Wang, X.; Chakrabarti, P. P.; Ognyanov, V. I.; Pettus, L. H.; Tamir, R.; Tan, H.; Tang, P.; Treanor, J. J. S.; Gavva, N. R.; Norman, M. H. Trisubstituted Pyrimidines as Transient Receptor Potential Vanilloid 1 (TRPV1) Antagonists with Improved Solubility Bioorg. Med. Chem. Lett. 2007, 17, 6539-6545 (Pubitemid 350026327)
76. Li, Q.; Chu, D. T. W.; Claiborne, A.; Cooper, C. S.; Lee, C. M.; Raye, K.; Berst, K. B.; Donner, P.; Wang, W.; Hasvold, L.; Fung, A.; Ma, Z.; Tufano, M.; Flamm, R.; Shen, L. L.; Baranowski, J.; Nilius, A.; Alder, J.; Meulbroek, J.; Marsh, K.; Crowell, D.; Hui, Y.; Seif, L.; Melcher, L. M.; Henry, R.; Spanton, S.; Faghih, R.; Klein, L. L.; Tanaka, S. K.; Plattner, J. J. Synthesis and Structure-Activity Relationships of 2-Pyridones: A Novel Series of Potent DNA Gyrase Inhibitors as Antibacterial Agents J. Med. Chem. 1996, 39, 3070-3088 (Pubitemid 26260312)
77. 1 Cannabinoid Receptor Antagonists J. Med. Chem. 2004, 47, 627-643 (Pubitemid 38129720)
78. Kim, I.-H.; Heirtzler, F. R.; Morisseau, C.; Nishi, K.; Tsai, H.-J.; Hammock, B. D. Optimization of Amide-Based Inhibitors of Soluble Epoxide Hydrolase with Improved Water Solubility J. Med. Chem. 2005, 48, 3621-3629 (Pubitemid 40664110)
79. Hodous, B. L.; Geuns-Meyer, S. D.; Hughes, P. E.; Albrecht, B. K.; Bellon, S.; Bready, J.; Caenepeel, S.; Cee, V. J.; Chaffee, S. C.; Coxon, A.; Emery, M.; Fretland, J.; Gallant, P.; Gu, Y.; Hoffman, D.; Johnson, R. E.; Kendall, R.; Kim, J. L.; Long, A. M.; Morrison, M.; Olivieri, P. R.; Patel, V. F.; Polverino, A.; Rose, P.; Tempest, P.; Wang, L.; Whittington, D. A.; Zhao, H. Evolution of a Highly Selective and Potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 Kinase Inhibitor J. Med. Chem. 2007, 50, 611-626 (Pubitemid 46332976)
80. Li, J. J.; Sutton, J. C.; Nirschl, A.; Zou, Y.; Wang, H.; Sun, C.; Pi, Z.; Johnson, R.; Krystek, S. R., Jr.; Seethala, R.; Golla, R.; Sleph, P. G.; Beehler, B. C.; Grover, G. J.; Fura, A.; Vyas, V. P.; Li, C. Y.; Gougoutas, J. Z.; Galella, M. A.; Zahler, R.; Ostrowski, J.; Haman, L. G. Discovery of Potent and Muscle Selective Androgen Receptor Modulators through Scaffold Modifications J. Med. Chem. 2007, 50, 3015-3025 (Pubitemid 47001244)